Lian Zhao

Dr. Lian Zhao

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2017 in Biomacromolecules
Verified
Journal Article
Closed access
QWQuan Wang
Quan Wang
RZRuirui Zhang
Ruirui Zhang
MLMingzi Lu
Mingzi Lu
GYGuoxing You
Guoxing You
YWYing Wang
Ying Wang
HZHong Zhou
Hong Zhou

16 June 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
KZKai Zhu
Kai Zhu
LWLijun Wang
Lijun Wang
YXYao Xiao
Yao Xiao
XZXiaoyong Zhang
Xiaoyong Zhang
GYGuoxing You
Guoxing You
GCGan Chen
Gan Chen
Oxygen is necessary for life and plays a key pivotal in maintaining normal physiological functions and treat of diseases. Hemoglobin-based oxygen carriers (HBOCs) have been studied and developed as a replacement for red blood cells (RBCs) in oxygen transport due to their similar oxygen-carrying capacities. However, applications of HBOCs are hindered by vasoactivity, oxidative toxicity, and a relatively short circulatory half-life. With advancements in nanotechnology, Hb encapsulation, absorption, bioconjugation, entrapment, and attachment to nanomaterials have been used to prepare nanomaterial-related HBOCs to address these challenges and pend their application in several biomedical and therapeutic contexts. This review focuses on the progress of this class of nanomaterial-related HBOCs in the fields of hemorrhagic shock, ischemic stroke, cancer, and wound healing, and speculates on future research directions. The advancements in nanomaterial-related HBOCs are expected to lead significant breakthroughs in blood substitutes, enabling their widespread use in the treatment of clinical diseases.Graphical Abstract

1 July 2020 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
JHJilin Hu
Jilin Hu
QWQuan Wang
Quan Wang
YWYing Wang
Ying Wang
GYGuoxing You
Guoxing You
PLPenglong Li
Penglong Li
HZHong Zhou
Hong Zhou

1 March 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MLMingzi Lu
Mingzi Lu
CZCaiyan Zhao
Caiyan Zhao
QWQuan Wang
Quan Wang
GYGuoxing You
Guoxing You
YWYing Wang
Ying Wang
HZHong Zhou
Hong Zhou

12 July 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
GCGan Chen
Gan Chen
GYGuoxing You
Guoxing You
YWYing Wang
Ying Wang
MLMingzi Lu
Mingzi Lu
WCWeina Cheng
Weina Cheng
HZHong Zhou
Hong Zhou
Introduction: This study compared the effects of hydroxyethyl starch 130/0.4, hydroxyethyl starch 200/0.5, and succinylated gelatin on oxidative stress and the inflammatory response in a rodent hemorrhagic shock model. Methods: Sodium pentobarbital-anesthetized adult male Wistar rats (200 g to 220 g) were subjected to a severe volume-controlled hemorrhage using arterial blood withdrawal (30 mL/kg to 33 mL/kg) and resuscitated with a colloid solution at the same volume as blood withdrawal (hydroxyethyl starch 130/0.4, hydroxyethyl starch 200/0.5, or succinylated gelatin). Arterial blood gas parameters were monitored. Malondialdehyde (MDA) content and myeloperoxidase (MPO) activity in the liver, lungs, intestine, and brain were measured two hours after resuscitation. The levels of tumor necrosis factor-alpha (TNF-α) and interleukin-6 in the intestine were also measured. Results: Infusions of hydroxyethyl starch 130/0.4, but not hydroxyethyl starch 200/0.5 or succinylated gelatin, significantly reduced MDA levels and MPO activity in the liver, intestine, lungs and brain, and it also inhibited the production of TNF-α in the intestine two hours after resuscitation. However, no significant difference between hydroxyethyl starch 200/0.5 and succinylated gelatin was observed. Conclusions: Hydroxyethyl starch 130/0.4, but not hydroxyethyl starch 200/0.5 or succinylated gelatin, treatment after hemorrhagic shock ameliorated oxidative stress and the inflammatory response in this rat model. No significant differences were observed after hydroxyethyl starch 200/0.5 or succinylated gelatin administration at doses of approximately 33 mL/kg.

3 October 2016 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
YWYing Wang
Ying Wang
LWLinli Wang
Linli Wang
WYWeili Yu
Weili Yu
DGDawei Gao
Dawei Gao
GYGuoxing You
Guoxing You
HZHong Zhou
Hong Zhou